ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism
- PMID: 35814382
- PMCID: PMC9256994
- DOI: 10.3389/fonc.2022.918778
ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism
Abstract
Aldehyde dehydrogenases 1 family member A1(ALDH1A1) gene codes a cytoplasmic enzyme and shows vital physiological and pathophysiological functions in many areas. ALDH1A1 plays important roles in various diseases, especially in cancers. We reviewed and summarized representative correlative studies and found that ALDH1A1 could induce cancers via the maintenance of cancer stem cell properties, modification of metabolism, promotion of DNA repair. ALDH1A1 expression is regulated by several epigenetic processes. ALDH1A1 also acted as a tumor suppressor in certain cancers. The detoxification of ALDH1A1 often causes chemotherapy failure. Currently, ALDH1A1-targeted therapy is widely used in cancer treatment, but the mechanism by which ALDH1A1 regulates cancer development is not fully understood. This review will provide insight into the status of ALDH1A1 research and new viewpoint for cancer therapy.
Keywords: aldehyde dehydrogenases; cancer stem cell; carcinogenesis; drug resistance; hepatocellular carcinoma.
Copyright © 2022 Yue, Hu, Hu, Guo, Zheng, Wang and Zhou.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.Cancer Chemother Pharmacol. 2002 Apr;49(4):309-21. doi: 10.1007/s00280-001-0412-4. Epub 2002 Feb 13. Cancer Chemother Pharmacol. 2002. PMID: 11914911
-
Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors.Eur J Med Chem. 2021 Jan 1;209:112940. doi: 10.1016/j.ejmech.2020.112940. Epub 2020 Oct 17. Eur J Med Chem. 2021. PMID: 33328099 Review.
-
Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines.Int J Biochem Cell Biol. 2016 Sep;78:248-259. doi: 10.1016/j.biocel.2016.07.017. Epub 2016 Jul 19. Int J Biochem Cell Biol. 2016. PMID: 27443528
-
Phosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancer.BMC Biol. 2017 Feb 13;15(1):10. doi: 10.1186/s12915-016-0335-5. BMC Biol. 2017. PMID: 28193222 Free PMC article.
-
ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review).Oncol Lett. 2025 Mar 4;29(5):213. doi: 10.3892/ol.2025.14959. eCollection 2025 May. Oncol Lett. 2025. PMID: 40093866 Free PMC article. Review.
Cited by
-
Tubular insulin-induced gene 1 deficiency promotes NAD+ consumption and exacerbates kidney fibrosis.EMBO Mol Med. 2024 Jul;16(7):1675-1703. doi: 10.1038/s44321-024-00081-7. Epub 2024 May 28. EMBO Mol Med. 2024. PMID: 38806641 Free PMC article.
-
The Molecular Context of Oxidant Stress Response in Cancer Establishes ALDH1A1 as a Critical Target: What This Means for Acute Myeloid Leukemia.Int J Mol Sci. 2023 May 27;24(11):9372. doi: 10.3390/ijms24119372. Int J Mol Sci. 2023. PMID: 37298333 Free PMC article. Review.
-
ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression.NPJ Precis Oncol. 2023 Jul 10;7(1):66. doi: 10.1038/s41698-023-00411-x. NPJ Precis Oncol. 2023. PMID: 37429899 Free PMC article.
-
Mitochondrial VDAC1 Silencing in Urethane-Induced Lung Cancer Inhibits Tumor Growth and Alters Cancer Oncogenic Properties.Cancers (Basel). 2024 Aug 26;16(17):2970. doi: 10.3390/cancers16172970. Cancers (Basel). 2024. PMID: 39272828 Free PMC article.
-
Integration of scRNA-seq and bulk RNA-seq to reveal the association and potential molecular mechanisms of metabolic reprogramming regulated by lactylation and chemotherapy resistance in ovarian cancer.Front Immunol. 2025 Feb 28;16:1513806. doi: 10.3389/fimmu.2025.1513806. eCollection 2025. Front Immunol. 2025. PMID: 40093000 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous